The Trump administration is exploring a five-year pilot program to include weight-loss drugs like Wegovy, Ozempic, Zepbound, ...

Ozempic has always come with side effects. The latest reported by users? Thinning hair and muscle loss. Experts break down ...

Note that some links may require registration or subscription. Justin Timberlake said he has been diagnosed with Lyme disease ...

The Trump administration is preparing a five-year pilot program that could allow Medicare and Medicaid to cover expensive GLP-1 weight loss drugs such as Ozempic, Wegovy, Mounjaro and Zepbound. If ...

The Washington Post says it has obtained documents that detail the five-year experiment involving state Medicaid programs and Medicare Part D plans. Plus: CMS has bumped up Medicare payments for ...

GLP-1s are bringing many changes to people's lives. An unexpected and less welcome one? A newfound aversion to meat and other ...

Eli Lilly is set to report Q2 2025 earnings on August 7, with consensus expecting $14.4 billion in revenue and $5.56 EPS, up 30-42% YoY. Learn more on LLY stock here.

For a while, Danish drugmaker Novo Nordisk A/S looked unstoppable. It was at the forefront of the weight-loss injection boom as people discovered that its Ozempic shot, originally developed to treat ...

Eli Lilly (LLY) stock and Novo Nordisk (NVO) stock gain as Trump administration to trial Medicare, Medicaid coverage for ...

The Trump administration outlines a plan to cover weight-loss drugs under Medicare and Medicaid, allowing certain state ...

The introduction of GLP-1s for weight loss has been a dysfunctional mess, thanks to pharmaceutical companies, insurance plans ...

President Trump on Thursday sent letters to 17 of the world’s biggest drugmakers demanding that they reduce some of their U.S ...